

Frédéric R Santer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4593683/publications.pdf>

Version: 2024-02-01

38
papers

1,453
citations

331670

21
h-index

434195

31
g-index

39
all docs

39
docs citations

39
times ranked

2766
citing authors

#	ARTICLE	IF	CITATIONS
1	Androgen receptor signaling in prostate cancer. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 413-427.	5.9	204
2	Inhibition of the Acetyltransferases p300 and CBP Reveals a Targetable Function for p300 in the Survival and Invasion Pathways of Prostate Cancer Cell Lines. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1644-1655.	4.1	188
3	Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. <i>Endocrine-Related Cancer</i> , 2010, 17, 241-253.	3.1	102
4	Down-regulation of Suppressor of Cytokine Signaling-3 Causes Prostate Cancer Cell Death through Activation of the Extrinsic and Intrinsic Apoptosis Pathways. <i>Cancer Research</i> , 2009, 69, 7375-7384.	0.9	78
5	Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. <i>Prostate</i> , 2018, 78, 1262-1282.	2.3	76
6	Nuclear Insulin-Like Growth Factor Binding Protein-3 Induces Apoptosis and Is Targeted to Ubiquitin/Proteasome-Dependent Proteolysis. <i>Cancer Research</i> , 2006, 66, 3024-3033.	0.9	68
7	The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling. <i>Oncogenesis</i> , 2017, 6, e342-e342.	4.9	68
8	Suppressor of Cytokine Signaling (SOCS)-1 Is Expressed in Human Prostate Cancer and Exerts Growth-Inhibitory Function through Down-Regulation of Cyclins and Cyclin-Dependent Kinases. <i>American Journal of Pathology</i> , 2009, 174, 1921-1930.	3.8	67
9	Therapy escape mechanisms in the malignant prostate. <i>Seminars in Cancer Biology</i> , 2015, 35, 133-144.	9.6	59
10	Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. <i>Endocrine-Related Cancer</i> , 2012, 19, 305-319.	3.1	56
11	Transcriptional coactivators p300 and CBP stimulate estrogen receptor- β signaling and regulate cellular events in prostate cancer. <i>Prostate</i> , 2011, 71, 431-437.	2.3	45
12	DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer. <i>Molecular Oncology</i> , 2016, 10, 879-894.	4.6	41
13	SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells. <i>Molecular Cancer Research</i> , 2016, 14, 574-585.	3.4	36
14	SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling. <i>Endocrine-Related Cancer</i> , 2010, 17, 525-538.	3.1	34
15	High-risk Human Papillomavirus E7 Oncoprotein Detection in Cervical Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 7067-7072.	7.0	33
16	Androgen receptor co-activators in the regulation of cellular events in prostate cancer. <i>World Journal of Urology</i> , 2012, 30, 297-302.	2.2	33
17	The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2722-2731.	4.1	32
18	Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer. <i>International Journal of Cancer</i> , 2018, 143, 1786-1796.	5.1	29

#	ARTICLE	IF	CITATIONS
19	Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy. <i>Oncotarget</i> , 2015, 6, 6105-6122.	1.8	28
20	IL6 sensitizes prostate cancer to the antiproliferative effect of IFN γ 2 through IRF9. <i>Endocrine-Related Cancer</i> , 2013, 20, 677-689.	3.1	25
21	Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer. <i>Steroids</i> , 2013, 78, 851-859.	1.8	24
22	Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells. <i>Molecular Oncology</i> , 2018, 12, 561-576.	4.6	21
23	Human papillomavirus type 16 E7 oncoprotein inhibits apoptosis mediated by nuclear insulin-like growth factor-binding protein-3 by enhancing its ubiquitin/proteasome-dependent degradation. <i>Carcinogenesis</i> , 2007, 28, 2511-2520.	2.8	19
24	p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer. <i>Endocrine-Related Cancer</i> , 2020, 27, 187-198.	3.1	17
25	MYC-Mediated Ribosomal Gene Expression Sensitizes Enzalutamide-resistant Prostate Cancer Cells to EP300/CREBBP Inhibitors. <i>American Journal of Pathology</i> , 2021, 191, 1094-1107.	3.8	14
26	The AR/NCOA1 axis regulates prostate cancer migration by involvement of PRKD1. <i>Endocrine-Related Cancer</i> , 2016, 23, 495-508.	3.1	13
27	Abstract 3350: Implications of the STAT6 pathway by interleukin-4 in prostate cancer. <i>Cancer Research</i> , 2012, 72, 3350-3350.	0.9	11
28	Identification of the FHL2 Transcriptional Coactivator as a New Functional Target of the E7 Oncoprotein of Human Papillomavirus Type 16. <i>Journal of Virology</i> , 2007, 81, 1027-1032.	3.4	10
29	Interleukin γ 4 induces a CD44 ^{high} /CD49b ^{high} PC3 subpopulation with tumor-initiating characteristics. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 4103-4112.	2.6	10
30	Studies on Steroid Receptor Coactivators in Prostate Cancer. <i>Methods in Molecular Biology</i> , 2018, 1786, 259-262.	0.9	7
31	Fractionated Radiation of Primary Prostate Basal Cells Results in Downplay of Interferon Stem Cell and Cell Cycle Checkpoint Signatures. <i>European Urology</i> , 2018, 74, 847-849.	1.9	4
32	Abstract 1622: Inhibition of the acetyltransferase p300 as a novel pro-apoptotic and anti-invasion approach for treatment of prostate cancer. , 2011, , .		1
33	228 THE MULTIKINASE INHIBITOR SORAFENIB SUPPRESSES AR EXPRESSION AND SIGNALING AND INDUCES APOPTOSIS OF CASTRATION THERAPY-RESISTANT PROSTATE CANCER CELLS. <i>Journal of Urology</i> , 2012, 187, .	0.4	0
34	Abstract 1726: Androgenic regulation of the anti-apoptotic Bcl-2 family member Mcl-1 in prostate cancer cells.. , 2013, , .		0
35	Abstract 618: Implications of inhibition of steroid receptor co-activator-1 in human prostate cancer. , 2014, , .		0
36	Abstract 5059: Androgenic signaling influences SOCS-3 in prostate cancer cells. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
37	Abstract A191: Augmenting the therapeutic efficacy of oncolytic LCMV-GP pseudotyped vesicular stomatitis virus via modulation of the innate immune system. , 2016, , .		0
38	Abstract 1020: p300 and CBP targeting in castration therapy resistant prostate cancer. , 2019, , .		0